Research ArticleOpen AccessGoogle Scholar indexed
Receptor Conversion between Primary Tumors and Distant Metastases in 121 Cases of Metastatic Breast Cancer
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Ultrasound, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Ultrasound, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 3 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Ultrasound, Peking University Cancer Hospital and Institute, Beijing, China
- 4 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 5 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 6 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 7 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Ultrasound, Peking University Cancer Hospital and Institute, Beijing, China
- 8 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 9 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 10 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 11 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- 12 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
International Journal of Clinical Medicine·Volume 04 (2013)·Pages 102–107·Published 26 February 2013·DOI10.4236/ijcm.2013.42020
Copy link · social · email
Abstract
The article published in Vol.4 No.2 102-107, 2013 has been withdrawn by the authors for further revision. This paper will be re-submitted to IJCM after the authors revise it.
KeywordsBreast CancerReceptor ConversionEstrogen ReceptorProgesterone ReceptorHER2
- F. Bray, P. McCarron and D. M. Parkin, “The Changing Global Patterns of Female Breast Cancer Incidence and Mortality,” Breast Cancer Research, Vol. 6, No. 6, 2004, pp. 229 239. doi:10.1186/bcr932
- L. D. Hoefnagel, M. J. van de Vijver, H. J. van Slooten, P. Wesseling, J. Wesseling and P. J. Westenend, “Receptor Conversion in Distant Breast Cancer Metastases,” Breast Cancer Research, Vol. 12, No. 5, 2010, p. R75.
- D. F. Hull, G. M. Clark, C. K. Osborne, G. C. Chamness, W. A. Knight and W. L. McGuire, “Multiple Estrogen Receptor Assays in Human Breast Cancer,” Cancer Re search, Vol. 43, No. 1, 1983, pp. 413 416.
- D. Gancberg, A. Di Leo, F. Cardoso, G. Rouas, M. Ped rocchi, A. Paesmans M. Verhest, C. Bernard Marty, M. J. Piccart and D. Larsimont, “Comparison of HER 2 Status between Primary Breast Cancer and Corresponding Dis tant Metastatic Sites,” Annals of Oncology, Vol. 13, No. 7, 2002, pp. 1036 1043. doi:10.1093/annonc/mdf252
- K. C. Lear Kaul, H. R. Yoon, B. K. Kleinschmidt De Masters, L. McGavran and M. Singh, “Her 2/Neu Status in Breast Cancer Metastases to the Central Nervous Sys tem,” Archives of Pathology & Laboratory Medicine, Vol. 127, No. 11, 2003, pp. 1451 1457.
- Y. Gong, D. J. Booser and N. Sneige, “Comparison of HER 2 Status Determined by Fluorescence in Situ Hy bridization in Primary and Metastatic Breast Carcinoma,” Cancer, Vol. 103, No. 9, 2005, pp. 1763 1769. doi:10.1002/cncr.20987
- J. Zidan, I. Dashkovsky, C. Stayerman, W. Basher, C. Cozacov and A. Hadary, “Comparison of HER 2 Over expression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metas tatic Disease,” British Journal of Cancer, Vol. 93, No. 5, 2005, pp. 552 556. doi:10.1038/sj.bjc.6602738
- C. X. Zhu and Y. Jin, “Clinical Significance of Ultra sound Guided Biopsy in Detecting the Expressions of ER, PR and CerbB 2 in Brest Carcinoma,” Journal of Medical Imaging, Vol. 22, No. 1, 2012, pp. 68 70.
- Z. F. Jiang, Y. H. Xu, S. Q. Song and Y. Sun, “Consensus of Endocrinotherapy for Breast Cancer,” Chinese Journal of Oncology, Vol. 28, No. 3, 2006, pp. 238 239.
- E. E. Lower, E. L. Glass, D. A. Bradley, R. Blau and S. Heffelfinger, “Impact of Metastatic Estrogen Receptor and Progesterone Receptor Status on Survival,” Breast Cancer Research and Treatment, Vol. 90, No. 1, 2005, pp. 65 70. doi:10.1007/s10549 004 2756 z
- C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S. W. Kau and W. F. Symmans, “Prognostic Impact of Discordance between Triple Receptor Measurements in Primary and Recurrent Breast Cancer,” Annals of Oncology, Vol. 20, No. 12, 2009, pp. 1953 1958. doi:10.1093/annonc/mdp263